Skip to main navigation Skip to search Skip to main content

Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The central role of the platelet in the pathophysiology of acute coronary syndromes (ACS) has been well established. The significant morbidity and mortality associated with ACS has fostered great interest and effort in identifying various antiplatelet and antithrombotic regimens as well as developing novel agents in order to abrogate the platelet and its associated prothrombotic effects. Aspirin remains the integral component of all therapeutic strategies for ACS. When used in combination with thienopyridines (i.e., clopidogrel), GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban), or both, patients have experienced improved outcomes in this setting. However, with more potent antiplatelet regimens comes an increased risk of bleeding. Thus, the search for more potent antiplatelet agents with a decreased risk of bleeding continues for this patient population.

Original languageEnglish
Title of host publicationContemporary Cardiology
PublisherSpringer International Publishing
Pages145-163
Number of pages19
DOIs
StatePublished - 2010
Externally publishedYes

Publication series

NameContemporary Cardiology
VolumePart F10915
ISSN (Print)2196-8969
ISSN (Electronic)2196-8977

Keywords

  • Acute coronary syndromes
  • Aspirin
  • Clopidogrel
  • Glycoprotein IIb/IIIa inhibitors
  • Non-T-segment-elevation myocardial infarction
  • Percutaneous coronary intervention
  • ST segment-elevation myocardial infarction
  • Thienopyridines

Fingerprint

Dive into the research topics of 'Antiplatelet Therapies in Unstable Angina and Non-ST Segment Elevation Myocardial Infarction'. Together they form a unique fingerprint.

Cite this